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Test and treat all as soon as possible
2013 will be remembered as an exceptional year in 
shaping our strategy to control HIV/AIDS. Indeed, a 
few weeks after the 30th anniversary of the discovery 
of the virus, a decisive step was made in deciding how 
to use antiretroviral therapy (ART) for treatment 
and prevention worldwide. New WHO public health 
guidelines recommended that ART should be started in 
all adults who reach a threshold of 500 CD4 cells per μL.1 
These guidelines were based on a strict review process 
and on the grounds of clinical and epidemiological 
beneﬁ ts. Yet their application at country level remains 
challenging and operational guidance is needed now the 
target population has expanded to almost 30 million 
people living with HIV.2
Statistical modelling was very useful in the decision-
making process that led to the 2013 WHO guidelines, 
complementing and putting into perspective the 
imperfect observational ART data. Furthermore, the 
constitution of an international network of experts 
who assembled and compared most available models 
considerably strengthened the approach.3 The con-
clusions reached were thus less debatable and the 
consensus achieved by this panel served the formulation 
of recommendations well, as in the early days of 
prevention of mother-to-child transmission of HIV.4
Recent modelling work5 concluded that the cost-
eﬀ ectiveness ratio of early ART in serodiscordant 
couples is very good. The HIV Modelling Consortium 
moves the debate several steps further with today’s 
report in The Lancet Global Health.6 By applying the best 
cost-beneﬁ t and cost-eﬀ ectiveness methods to four 
distinct scenarios of generalised (South Africa, Zambia) 
and concentrated (Vietnam, India) epidemics, and 
considering high or moderate ART coverage at baseline, 
the Consortium provides a very powerful message: 
enforcing the 2013 WHO ART eligibility criteria and 
increasing uptake are both very cost-eﬀ ective strategies 
according to international standards. Additionally, 
moving towards treatment for all adults living with 
HIV (or preferably all members of speciﬁ c populations 
in concentrated epidemics) is an excellent long-term 
investment, competing extremely well with other high-
priority health interventions. These conclusions were 
obtained in all scenarios combining high ART thresholds 
and increased uptake and with most models (the South 
African context, for instance, was explored with seven 
diﬀ erent models and two diﬀ erent strategies). The 
incremental eﬀ ectiveness ratios varied substantially 
from model to model but were always well below the 
corresponding country’s per capita gross domestic 
product. In some situations, the current guidelines and 
ART coverage status quo were clearly dominated—ie, 
improved health outcomes were achieved with the new 
strategies while reducing costs. Of note, the beneﬁ ts 
increased over time, although the highest-impact 
inter ventions were not cost-saving over the 20-year 
horizon. The authors acknowledge that some of their 
assumptions could be revisited should new data become 
available, but the reader should be easily convinced that 
their conclusions are robust.
Having addressed the “What if?” question, the 
next question is clearly “How should increasing ART 
thresholds and uptake be achieved?” This operational 
research challenge should be investigated without 
further delay. It is fortunate that the next 2–3 years will 
see direct estimates from randomised controlled trials of 
severe morbidity and mortality reduction in relation to 
early ART.7,8 Furthermore, the population acceptability 
and feasibility of universal test and treat introduced 
within combination prevention programmes will be 
documented in generalised epidemics.9,10
Clinicians, public health programme specialists, and 
national and international decision makers now have 
much clearer evidence for enlarging as rapidly as possible 
the ART eligibility criteria, taking all actions to increase 
coverage, and starting to plan for universal testing and 
treatment of those living with HIV. The priority remains 
to reach those most in need ﬁ rst,1 but there is also a 
clear urgency for short-term plans to achieve the overall 
target. The HIV Modelling Consortium has chosen to use 
a 2-year scaling-up period in their modelling exercise,6 
which is probably overoptimistic in many settings. It 
should not exceed 5 years, though, or the anticipated 
beneﬁ ts will be lesser and the overall costs higher.
Paying now rather than forever has never been as 
relevant as a global health solution to the HIV pandemic 
than in 2013. The relative success of the ongoing 
replenishment session for the Global Fund11 is a posi tive 
signal, although still insuﬃ  cient considering the evidence-
based targets that are set for the coming years. Finally, it 
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is probably time to change the meaning of the acronym 
TasP, which currently stands for treatment as prevention. 
It is too restrictive to reﬂ ect our evolving thinking around 
the use of ART. To be in line with the available evidence, 
an alternative slogan for 2014 onwards could be: Test and 
treat All as Soon as Possible (TASP).
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